Ensuring Communication in Hospice by Oncology Study (ECHO)
|Ovarian Cancer Cervical Cancer Uterine Cancer Head and Neck Cancer Sarcoma Melanoma||Behavioral: communication with oncology team|
|Study Design:||Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Supportive Care
|Official Title:||Ensuring Communication in Hospice by Oncology Study (ECHO)|
- Evaluate the feasibility of implementing the Ensuring Communication in Hospice by Oncology Study (ECHO) intervention by patients' family caregivers and their oncology providers. [ Time Frame: 2 Years ]ECHO will be considered feasible if greater than 70% of participants have > 50% of the scheduled phone contact with the oncology team during hospice care, which will be documented in the patient's medical record. Feasibility will also be demonstrated if greater than 70% of the family caregivers completing the questionnaires do so greater than 50% of the time they were scheduled. Finally, feasibility will also be demonstrated if caregivers are able to be contacted and decide upon participation within 5 days of patient hospice enrollment.
- Prospectively explore the satisfaction with the overall experience of family caregivers through questionnaires when receiving the ECHO intervention. [ Time Frame: 2 Years ]
- Prospectively explore rates of health service utilization in the patients receiving the ECHO intervention in terms of (1) hospice disenrollment; (2) hospitalization; and (3) emergency department visits [ Time Frame: 2 Years ]
- Prospectively explore the levels of stress of family caregivers through questionnaires when receiving the ECHO intervention. [ Time Frame: 2 years ]
- Prospectively explore decision making regret of family caregivers through questionnaires when receiving the ECHO intervention. [ Time Frame: 2 years ]
|Actual Study Start Date:||January 2014|
|Study Completion Date:||January 2017|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
Experimental: communication with oncology team
oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
Behavioral: communication with oncology team
Oncology team will contact patients and families via telephone at specific intervals
There are four parts of the study. First, the participant will receive phone calls twice a week from the oncology team to check in with how the transition to hospice is going. Second, the participant may choose to have an appointment with the Massachusetts General Hospital oncology team to discuss any questions or concerns regarding cancer care or the transition to hospice. Third, each week of hospice care, the participant will be asked to complete a set of questionnaires at a time that is convenient for them either by phone or by email. These questions will ask the participant about their recent thoughts and feelings about their experience with hospice and as a caregiver. The questions will take less than 15 minutes to answer. Fourth, after hospice care has ended, the participant will be called by the oncology team to again check in and about a month later, the participant will also be contacted by phone to complete a set of questionnaires, again asking about their thoughts and feelings about your experience with hospice and as a caregiver.
For all of the questionnaires, the participant may skip any questions that the participant prefers not to answer. The responses will remain confidential and will be available only to study staff members who are trained in confidentiality and research ethics.
Additionally, during the research study, the investigators will obtain information from the participant's loved one's Massachusetts General Hospital electronic medical record that is relevant to the participation in the study for up to 6 months. If he/she has visited another hospital during this time, the investigator will also ask the participant for their permission to obtain the medical records from this visit.
The participant will not receive any compensation for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02069769
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Jennifer Temel, MD||Massachusetts General Hospital|